# Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

> **NCT04786067** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Kidney Transplant Immunosuppression

## Interventions

- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT04786067
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-07-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04786067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04786067, "Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04786067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*